ABSTRACT
Background The earliest coronavirus disease-2019 (COVID-19) cases in Central Asia were announced in March 2020 by Kazakhstan. Despite the implementation of aggressive measures to curb infection spread, gaps remain in the understanding of the clinical and epidemiologic features of the regional pandemic.
Methods We did a retrospective, observational cohort study of patients with laboratory-confirmed COVID-19 in Kazakhstan between February and April 2020. We compared demographic, clinical, laboratory and radiological data of patients with different COVID-19 severities on admission. Univariable and multivariable logistic regression was used to assess factors associated with disease severity and death. Whole-genome SARS-CoV-2 analysis was performed in 53 patients without a recent history of international travel.
Findings Of the 1072 patients with laboratory-confirmed COVID-19 in March-April 2020, the median age was 36 years (IQR 24–50) and 484 (45%) were male. On admission, 683 (64%) participants had mild, 341 (32%) moderate, and 47 (4%) severe-to-critical COVID-19 manifestation; 20 deaths (1.87%) were reported at study exit. Multivariable regression indicated increasing odds of severe disease associated with older age (odds ratio 1.05, 95% CI 1.03-1.07, per year increase; p<0.001), the presence of comorbidities (2.13, 95% CI 1.07-4.23; p<0.031) and elevated white blood cell count (WBC, 1.14, 95% CI 1.01-1.28; p<0.032) on admission, while older age (1.09, 95% CI 1.06-1.12, per year increase; p<0.001) and male sex (5.97, 95% CI 1.95-18.32; p<0.002) were associated with increased odds of death. The Kazakhstan SARS-CoV-2 isolates grouped into seven distinct lineages O/B.4.1, S/A.2, S/B.1.1, G/B.1, GH/B.1.255, GH/B.1.3 and GR/B.1.1.10.
Interpretation Older age, comorbidities, increased WBC count, and male sex were risk factors for COVID-19 disease severity and mortality in Kazakhstan. The broad SARS-CoV-2 diversity suggests multiple importations and community-level amplification, likely predating the declaration of state emergency. Continuous epidemiologic and genomic surveillance may be critical for a better understanding of the regional COVID-19 dynamics.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04627194
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT04627194
Funding Statement
Genomic studies were funded by the Ministry of Education and Science of the Republic of Kazakhstan (Grant# AP08052352).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The retrospective registered (https://clinicaltrials.gov/ct2/show/NCT04627194) cohort study was approved by the Research Ethics Board of Semey Medical University as an anonymized epidemiological study, for which the requirement for informed consent was waived due to the pandemic state and urgent need to collect and analyze data. Virological samples used in genomic studies were anonymized and all genomic study procedures were approved by the Ethics Committee of the National Centre for Biotechnology (Nur-Sultan, Kazakhstan).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The retrospective cohort study was approved by the Research Ethics Board of Semey Medical University as an anonymized epidemiological study, for which the requirement for informed consent was waived due to the pandemic state and urgent need to collect and analyze data. Virological samples used in genomic studies were anonymized and all genomic study procedures were approved by the Ethics Committee of the National Centre for Biotechnology (Nur-Sultan, Kazakhstan).
